First-of-its-kind research at the Minneapolis VA has found no long-term benefits for patients taking opioid medications for chronic pain — a finding that is likely to strengthen the case for reducing use of the addictive medications that have been responsible for a sharp rise in drug overdoses and deaths.
Focusing on patients who suffer from chronic back pain or arthritic knees and hips, the study compared 120 who didn't receive opioids with 120 who did as part of their pain management. After a year, pain levels dropped by the same amount in both groups, and pain intensity decreased more in those who didn't receive opioids such as hydrocodone or oxycodone.
Meanwhile, treatment-related complications were more common in the opioid group.
"The data don't support opioids' reputation as painkillers," said Dr. Erin Krebs, who led the study, called Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE). She presented the findings Wednesday at the annual research day at the Minneapolis VA Medical Center, and in April to the Society of General Internal Medicine.
Krebs' findings could influence state and federal policies on opioid prescribing. A Minnesota task force has debated over the past year whether to discourage the use of opioids for patients with chronic pain, largely because of the relative lack of evidence that the drugs work for such patients.
"This is a valuable reinforcer of what our group is moving to," said Dr. Chris Johnson, a member of the opioid task force and a leading critic of opioid prescribing. "And if pain doctors still think these medicines are effective, then they have a lot of explaining to do, and their competence and professionalism deserve to be challenged."
Attitudes about opioid medications and their addictive hazards evolved so rapidly over the five years of the study that Krebs said she isn't sure a follow-up study would receive ethical clearance today — to keep one group of chronic pain patients on opioids. It wasn't always so. At first, critics raised the opposite question: the ethics of denying half the study group access to opioids.
"This was an incredibly challenging trial to execute," Krebs said, noting that at the outset 37 percent of the patients placed in the non-opioid group actually wanted those drugs for their pain.